Global Continuous Glucose Monitoring Systems Market Strategic Research Report

The global continuous glucose monitoring (CGM) systems market has emerged as one of the most consequential segments within medical devices, driven by the escalating prevalence of diabetes mellitus and the broader shift toward real-time, patient-managed chronic disease care. Valued at approximately USD 8.4 billion in 2024, the market encompasses wearable biosensor devices, transmitters, receivers, and integrated software platforms that enable patients and clinicians to track interstitial glucose levels continuously without repeated fingerstick testing. The commercial significance of CGM extends well beyond diabetes management into intensive care monitoring, sports performance, and preventive metabolic health—a broadening of addressable populations that is reshaping competitive strategy among established device manufacturers and emerging technology entrants alike.

Three primary forces are propelling market expansion through the forecast horizon. First, the global diabetes burden continues to intensify: the International Diabetes Federation estimates that more than 537 million adults lived with diabetes in 2021, a figure projected to exceed 780 million by 2045, directly expanding the patient pool eligible for CGM therapy. Second, reimbursement expansion by major payers—most notably CMS's 2023 expansion of Medicare CGM coverage to all insulin-using beneficiaries in the United States, and analogous policy shifts across Germany, France, and the United Kingdom—has materially reduced the out-of-pocket cost barrier that historically constrained adoption in Type 2 diabetes populations. Third, the integration of CGM data streams with automated insulin delivery systems and smartphone-based digital therapeutics has created a clinical evidence base that increasingly supports CGM as standard of care rather than supplemental monitoring. The principal restraint is the persistent cost burden in lower-middle-income countries, where consumable sensor replacement costs remain prohibitive and reimbursement frameworks are nascent, limiting penetration across large diabetic populations in South and Southeast Asia and Sub-Saharan Africa.

This strategic research report delivers a comprehensive quantitative and qualitative assessment of the global CGM systems market from 2019 through 2032, segmenting the landscape by product type, application, and geography across five regions and six key countries. The report profiles ten leading companies with revenue context, competitive positioning analysis, and assessment of recent M&A and product launch activity. It is designed primarily for corporate strategy teams evaluating portfolio adjacencies, investment analysts modeling device sector growth, M&A advisors conducting target screening, and procurement managers benchmarking sourcing strategies within integrated health systems.